Compare Viatris Inc (VTRS) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Wheaton Precious Metals Corp — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while Wheaton Precious Metals Corp trades at $110.88 (market cap $46.54B). The key difference: Wheaton Precious Metals Corp is far larger — about 2.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| VTRS | WPM | |
|---|---|---|
Market Cap | $19.79B | $46.54B |
Sector | Health | Basic Materials |
52-Week High | $17.39 | $165.72 |
52-Week Low | $8.74 | $91.00 |
Enterprise Value | $32.00B | $44.39B |
Dividend Yield | 2.83% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Wheaton Precious Metals (WPM) trades at $109.96, up 5.55% today, with a bearish technical signal but strong fundamentals. The company reported record revenue of $2.31B in 2025, net income of $1.47B, and has beaten earnings estimates for three consecutive quarters. Operating cash flow surged to $1.90B in 2025, supporting a positive outlook.
WPM offers growth potential with an 80% analyst buy rating and a consensus price target of $161.75, implying significant upside. Risks include exposure to precious metal price volatility and a high P/E ratio of 26.14. The stock's current discount to target presents a buying opportunity for long-term investors, contingent on stable metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
